Galectin closes $9.8M direct equity offering

|About: Galectin Therapeutics,... (GALT)|By:, SA News Editor

Galectin Therapeutics (GALT -11.3%) inks a securities purchase agreement with institutional investors for the sale of 4,761,900 shares of common stock at $2.06 plus five-year warrants to purchase up to 3,571,425 shares of common at $2.50.

Net proceeds will fund clinical trial expenses, R&D and general corporate purposes. Closing date is November 25.

Subscribe for full text news in your inbox